Belarus is taking a significant step toward pharmaceutical independence.

“Farmland” from Nesvizh is launching its own production of antibiotic substances, and the technology will be provided by an Indian partner – Kopran, one of the world’s leaders in this field.

Until now, substances for life‑saving medicines were purchased abroad.

Now the situation is changing.

And this is not just a business headline – it’s a matter of treatment accessibility for millions of people.

Why imported substances are a risk

I often hear from fellow pharmacists: “While we buy substances abroad, we are dependent on logistics, prices, and politics.”

And that’s true.

Any disruption in the supply chain can reduce the number of life‑saving drugs on pharmacy shelves.

Antibiotics are not a luxury item.

They are what save lives in cases of pneumonia, sepsis, and postoperative complications.

A delivery delay or price spike puts patients at risk.

By the way,